about us pic3long

ABOUT US

hd innovation en partage

Oncology, one of Pierre Fabre main priorities

Pierre Fabre Laboratories has set oncology as its main priority within its Medical Care division, with a core focus on targeted therapies. We take a holistic approach to cancer care focusing not only on treatment but prevention and support.

As a partner of choice, we are continuing to strengthen our portfolio with precision medicine in solid tumours and haematology. Together with the oncology community, we strive to address the most critical needs in cancer today and continue to deliver clinically meaningful treatments.

LEARN MORE ON PIERRE-FABRE.COM

Pierre Fabre - New ways to care

cover corporate video website_1

Pierre Fabre Laboratories

For more than 60 years we have been innovating relentlessly to take care of everyone.

We are empowered by humanistic values inherited from our founder and perpetuated through our corporate purpose: " Every time we care for a single person, we make the whole world better"
We are fortunate to be owned by a government-recognised public interest foundation, the Pierre Fabre Foundation which allows us to focus on the long-term for the good of patients.

Watch the video to know more about Pierre Fabre Laboratories.

LEARN MORE ON PIERRE-FABRE.COM

Discover our Expertise

Our dual expertise- pharmaceutical and dermo-cosmetics- help us offer a holistic approach to care: prevent, treat and support

skin

SKIN, HAIR & ORAL HEALTH

Taking care of your skin, hair and oral health

Treating cancer v2

CANCER

Treating cancer

Chronic diseases2

CHRONIC DISEASES

Treating chronic diseases

ailment picture

AILMENTS

Treating everyday ailments

LEARN MORE ABOUT OUR EXPERTISE

HealthCare Professionals

This is an international website for BRAFTOVI® + MEKTOVI® dedicated to Healthcare professionals

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that:

I am Healthcare Professional outside the US and I have read the information above.

Patients

This is an international website for BRAFTOVI^® + MEKTOVI^® dedicated to Healthcare Professionals.

I am a patient outside the US.

https://www.pierre-fabre.com/en

REFERENCES

1. BRAFTOVI^® Summary of Product Characteristics. Pierre Fabre Médicament.
2. MEKTOVI^® Summary of Product Characteristics. Pierre Fabre Médicament.
3. Dummer R, et Al. COLUMBUS 5-Year Update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAFV600–mutant melanoma. J. Clin. Oncol. (2022). DOI: 10.1200/JCO.21.026595-year publication.
4. Dummer R, Ascierto PA, Gogas HJ et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, Phase 3 trial. Lancet Oncol 2018;19(10):1315–1327.
5. Ascierto PA, Dummer R, Gogas HJ et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised Phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF^V600-mutant melanoma. Eur J Cancer 2020;126:33–44.
6. Gogas HJ, Flaherty KT, Dummer R et al. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. Eur J Cancer 2019;119:97–106.
7. Gogas HJ, Dummer R, Ascierto PA et al. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: results from a multicentre, open-label, randomised, Phase III study (COLUMBUS). Eur J Cancer 2021;152:116–128.
8. Musoro JZ, Bottomley A, Coens C et al. Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma. Eur J Cancer 2021;104:169–181.
9. Trojaniello C, Festino L, Vanella V et al. Encorafenib in combination with binimetinib for unresectable metastatic melanoma with BRAF mutation. Expert Rev Clin Pharmacol 2019;12(3):259–266.
10. Heinzerling L, Elgentler TK, Fluck M et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 2019;4(3):e000491.
11. Dummer R, Ascierto PA, Gogas HJ et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol 2018;19(5):603–615.
12. Lebbe C, Lorigan P, Ascierto PA et al. Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study). Eur J Cancer 2012;48(17):3205–3214.
13. Gogas HJ, et al. Updated Quality of Life (QoL) of encorafenib + binimetinib (COMBO450) versus (vs) vemurafenib (VEM) from COLUMBUS Part 1 Phase III study in BRAF-mutant melanoma. Presented at the 16th International Congress of the Society for Melanoma Research (SMR). November 20–23, 2019, Salt Lake City, Utah. USA.

This is an international website for BRAFTOVI^®+MEKTOVI^®. IMPORTANT: the information on this website is based on the European Summaries of Product Characteristics . Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

HQ-MEK-09-23-2300001 Last update: September 2023

Pierre Fabre

BRAFTOVI® is a trademark of Array BioPharma Inc., a wholly owned subsidiary of Pfizer Inc. MEKTOVI® is a trademark of Array BioPharma Inc. a wholly owned subsidiary of Pfizer Inc. © 2023, Pierre Fabre all rights reserved